Title: Seroprevalence of chikungunya and o'nyong-nyong viruses in Senegal, West

Africa

Authors: Prince Baffour Tonto[1,2], Mouhamad Sy[3], Ibrahima Mbaye Ndiaye[3], Mariama

Toure[3], Amy Gaye[3], Mariama Aidara[3], Amadou Moctar Mbaye[3], Abdoulaye Kane Dia[3,4],

Mamadou Alpha Diallo[3], Jules Francois Gomis[3], Mamadou Samba Yade[3], Younous

Diedhiou[3], Baba Dieye[3], Khadim Diongue[3], Mame Cheikh Seck[3], Aida S. Badiane[3],

Bobby Brooke Herrera[1,2]*, Daouda Ndiaye[3]

Affiliations:

1 Rutgers Global Health Institute, Rutgers University, New Brunswick, NJ, USA

2 Department of Medicine, Division of Allergy, Immunology, and Infectious Diseases and

Child Health Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, New

Brunswick, NJ, USA

3 International Research Training Center on Genomics and Health Surveillance

(CIGASS), Cheikh Anta Diop University, Dakar, 16477, Senegal

4 Laboratoire d'ecologie vectorielle et parasitaire

*****Corresponding Author**: BBH, bherrera@globalhealth.rutgers.edu

Abstract

Background

Arthritogenic alphaviruses such as chikungunya (CHIKV) and o'nyong-nyong (ONNV) viruses have shown capacity to cause widespread epidemics, with recurrent and sporadic outbreaks occurring throughout sub-Saharan Africa.

Methods

We analyzed the seroprevalence for CHIKV and ONNV in 470 non-febrile subjects from three regions in Senegal (Sindia, 2018; Thies, 2018; and Kedougou, 2022/2023) using retrospective samples. We assessed the presence of anti-CHIKV IgG and neutralizing antibody titers against CHIKV and ONNV via enzyme-linked immunosorbent assay (ELISA) and microneutralization tests, respectively, and determined risk factors of CHIKV and ONNV exposure by binary logistic regression.

Results

The overall alphavirus seroprevalence based on an anti-CHIKV viral like particle (VLP) IgG ELISA was 38.5%, with rates varying geographically: Kedougou (48.6%), Thies (31.9%), and Sindia (14.9%). Neutralizing antibody titers revealed CHIKV and ONNV seroprevalence rates of 7.4% and 9.8%, respectively, with significant variations by region and age group. Cross-reactivity analysis showed that 82.9% of CHIKV cases exhibited a neutralizing response to ONNV, while 71.7% of ONNV cases cross-neutralized CHIKV. Residents of Thies had significantly higher odds of CHIKV infection (aOR, 3.147; 95% CI: 1.164-8.510) while ONNV infection was more likely in Kedougou (aOR, 3.888; 95% CI: 1.319-11.466). Furthermore, older age (> 40 years) was a significant risk factor both

45 CHIKV (aOR, 2.094; 95% CI: 0.846-5.185) and ONNV infection (aOR, 2.745; 95% CI:

46 1.212-6.216).

Conclusions

48 Our study confirms the co-circulation of CHIKV and ONNV in Senegal, highlighting their

49 geographic and demographic distribution. These findings underscore the need for

50 continued surveillance, alphavirus testing, and tailored public health strategies to mitigate

51 their impact in Senegal.

Introduction

Arboviruses transmitted by mosquitoes pose a growing global health threat, significantly impacting morbidity and mortality. Among these, chikungunya (CHIKV) and o'nyong-nyong (ONNV) viruses are notable members of the alphavirus genus, recognized for their substantial effects on human health (1, 2). CHIKV, first isolated in Tanzania in 1952, has caused major outbreaks across Africa, Asia, and the Americas (3-5). Its transmission primarily involves *Aedes* mosquitoes, and its capacity for widespread dissemination was highlighted by the 2004 epidemic that originated in Kenya and rapidly extended to various regions, including the Indian Ocean islands and South and Southeast Asia (1, 5-7). By 2011, CHIKV reached the Western Hemisphere, spreading through the Caribbean and South America by 2014, resulting in hundreds of thousands of infections (8-10).

ONNV, identified in Uganda in 1959, has caused significant epidemics primarily in East and West Africa, with major outbreaks recorded in the 1950s and early 1990s (11-13). Transmitted by *Anopheles* mosquitoes, ONNV remains largely confined to the African continent (6). The first major epidemic occurred from 1959 to 1962, affecting over 2 million people across East and West Africa (14, 15). A subsequent outbreak from 1996 to 1997 primarily impacted Uganda, Kenya, and Tanzania, with infection rates ranging from 45-68% (14, 16). Despite its geographical confinement, ONNV has been detected in travelers returning from endemic regions (17).

Clinically, infections with CHIKV and ONNV are generally self-limiting but can present a spectrum of symptoms including fever, arthralgia, rash, headache, and malaise (18, 19). CHIKV is particularly associated with persistent arthralgia in patients (20).

Although ONNV is endemic to Africa, comprehensive data on its morbidity and mortality

are limited due to inadequate surveillance. The clinical features of alphavirus infections

closely resemble those caused by other pathogens including *Plasmodium* (malaria) or

Salmonella (typhoid fever) species, which are endemic in many West African countries

(21-26). This symptom overlap complicates diagnosis and can lead to underreporting of

CHIKV and ONNV, as their symptoms may be misattributed to other febrile illnesses.

In West Africa, including Senegal, autochthonous cases of CHIKV have been

reported since 1960, with periodic outbreaks continuing up to 2023 (27-31). Despite these

occurrences, current data on the seroprevalence of CHIKV and ONNV in Senegal

remains limited. This study aims to address this knowledge gap by investigating the

seroprevalence of CHIKV and ONNV in Senegal. Given the antigenic similarities between

these viruses, our approach focuses on using microneutralization assays to help

differentiate between them to provide a more in-depth understanding of their prevalence.

By enhancing our knowledge of the epidemiological landscape of CHIKV and ONNV in

Senegal, we hope to inform public health strategies and contribute valuable insights into

the broader context of arboviral transmission in West Africa.

Methods

Study Population and Ethics Statement

The samples included in our study were originally collected as part of malaria

and non-malarial surveillance among residents of Thies, Sindia, and Kedougou,

Senegal. Samples from Thies and Sindia were part of the surveillance of non-malarial

febrile illnesses, while samples from Kedougou were part of genomic surveillance of

malaria. Informed consent was obtained from all subjects and/or their legal guardians

for the initial sample collection as well as for its future use. All methods were performed

in accordance with the guidelines and regulations set forth by the Declaration of

Helsinki. The primary studies under which the samples and data were collected

received ethical clearance from the CIGASS Institutional Review Board (IRB) (Protocol

numbers: SEN15/46, 19300, and SEN14/49). All excess samples and corresponding

data were banked and de-identified prior to the analyses. This study received and

exemption determination from the Rutgers Robert Wood Johnson Medical School IRB.

CHIKV viral like particle (VLP) ELISA

CHIKV VLPs (20 ng per well; Native Antigen) were coated onto Nunc Maxisorp

96-well plates (ThermoFisher) overnight, followed by blocking (1X PBST, 1% BSA;

ThermoFisher) for 1 hour, then washing (1X PBST three times) and incubation with

primary antibodies for 2 hours (serum at 1:400 dilution) at room temperature. The plates

were washed three times with 1X PBST and bound sera were reacted with secondary

antibodies (anti-human IgG conjugated with horseradish peroxidase [HRP];

ThermoFisher), according to the manufacturer's instructions. The plates were washed

three more times and allowed to develop with 1-Step TMB ELISA Substrate

(ThermoFisher), according to the manufacturer's instructions. The OD at 450 nm was

read with a reference wavelength of 650 nm using an ELISA reader (Diasource). We

interpreted the ELISA assay as follows: 1) sample absorbance / negative control

absorbance ≤ 1.5, negative; 2) sample absorbance / negative control absorbance > 1.5,

positive.

Serum Microneutralization Assays

Microneutralization assays were performed to detect neutralizing antibodies

against CHIKV and ONNV in samples that were IgG positive for CHIKV VLP. Sera were

diluted in a two-fold series from 1:40 to 1:10,240 in PBS in a 96-well plate. For each

dilution, contact was performed with 100 plaque forming units (PFU) of CHIKV (BEI

Resources: NR-56523) or ONNV (BEI Resources: NR-51661) for one hour at 37°C in a

5% CO_2 incubator. The complexes were then added to Vero cells (ATCC) CCL-81, 1.3 x

10^5 cells per well. After 3-4 days of incubation, the cytopathogenic effects were

investigated by 0.2% crystal violet (SigmaAldrich) staining. After staining for 2-4 hours,

the plates were washed with copious amounts of tap water. For negative controls, at least

3 alphavirus-naïve serum samples were used to incubate with CHIKV or ONNV prior to

pipetting onto the Vero cells per plate. For positive controls, 100 PFU of CHIKV or ONNV

without any contact with serum were placed on Vero cells in triplicate per plate.

The neutralizing titer was defined as the inverse of the highest dilution resulting in

an infectious reduction of 50%. A titer lower than 1:40 was considered as negative if

cytopathogenic effects were not observed. Samples were considered as positive if the

titer was ≥1:40, i.e., positive for ONNV if ONNV titers were at least two-fold higher than

CHIKV titers, and CHIKV positive if CHIKV titers were at least four-fold higher than ONNV

titers (32). The threshold was lower for ONNV than CHIKV because of the unique one-

way cross-reactivity between CHIKV and ONNV, i.e., CHIKV antibodies are more likely

to cross-react with ONNV antigens than ONNV antibodies with CHIKV antigens (33). All

other results were interpreted as equivocal. 20 Senegalese serum samples that were

previously determined to be alphavirus-naïve, were used to validate the assay. Each

assay used at least 4 alphavirus-naïve serum samples as negative controls.

Statistical Analysis

Categorical variables are represented as case counts and proportions, with

differences assessed using the Chi-square or Fisher exact test as appropriate. To

estimate the association between seroprevalence of alphavirus and demographics

factors, including age group, gender, city, a univariate binary logistic regression analysis

was performed. The adjusted odd ratios of the independent variables were computed by

adjusting for age and gender as confounding variables. Statistical analyses were

conducted using IBM SPSS statistics software version 28. The map of Senegal, heatmap,

and graph representing rates and percentages of CHIKV and ONNV neutralizing

antibodies were generated using R version 4.3.2 and Prism version 10.2.0.

Results

Characteristics of study subjects

A total of 470 samples collected from non-febrile subjects were included in the

study. These samples were collected from three locations in Senegal: Sindia (n=94),

Thies (n=94), and Kedougou (n=282). The samples from Sindia and Thies were malaria-

negative by rapid diagnostic testing, whereas the samples from Kedougou were from

subjects with malaria. The study population were relatively young, with approximately

48% of them aged 20 years or younger, and consisted of fewer females, comprising

44.89%. (Table 1).

Prevalence of CHIKV and ONNV

We first employed an anti-CHIKV VLP IgG ELISA to screen 470 non-febrile serum samples. The CHIKV VLP antigen is specifically designed to detect IgG antibodies against CHIKV but can also recognize cross-reactive antibodies against related alphaviruses. Of the 470 samples tested, 181 were positive, resulting in an estimated alphavirus prevalence of 38.5%. Seroprevalence rates varied by location. Sindia had a rate of 14.9%, Thies had 31.9%, and Kedougou had 48.6% (Table 1).

Moreover, the microneutralization assay, regarded as the gold standard for identifying prior exposure to a specific virus was utilized to differentiate exposure to CHIKV and/or ONNV. Among the CHIKV IgG positive samples, 117 were available to assess neutralizing antibodies against CHIKV and/or ONNV. The prevalence of neutralizing antibodies against CHIKV and ONNV varied by location, gender, and age group. The prevalence rates of CHIKV neutralizing antibodies were 6.4% in Sindia, 19.1% in Thies, and 3.9% in Kedougou (Table 1). By gender, 7.0% for males and 8.0% for females had CHIKV neutralizing antibodies (Table 2). Across age groups, the prevalence was 7.6% in subjects aged ≤20 years, 5.3% in subjects aged 21 to 40 years, and 14.8% in those over 40 years (Table 2). For ONNV, the neutralizing antibody prevalence rates were 4.3% in Sindia, 4.3% in Thies, and 13.5% in Kedougou (Table 1). The prevalence of ONNV neutralizing antibodies was 10.2% for males and 9.5% for females (Table 2). Age-stratified prevalence showed a rate of 8.5 % in subjects aged ≤20 years, 8.0% in subjects aged 21 to 40 years, and 20% in those over 40 years (Table 2).

Overall, 7.4% of the study subjects had neutralizing antibodies against CHIKV, 9.8% against ONNV, 5.1% were equivocal for both CHIKV and ONNV, and 2.6% were

negative, indicating prior exposure to other related alphaviruses (Table 1, Fig. 2A). Moreover, of the subjects with CHIKV neutralizing antibodies, 82.9% had cross-neutralizing antibodies against ONNV (Fig. 1B-C). However, subjects with ONNV neutralizing antibodies, 71.7% had cross-neutralizing antibodies against CHIKV (Fig. 2B-C).

Risk factors for CHIKV and ONNV infection

Univariate logistic regression, adjusted for age and gender, revealed that being a resident of Thies (aOR, 2.384; 95% CI: 1.151-4.939) or Kedougou (aOR, 5.591; 95% CI: 3.001-10.418) were associated with increased odds of exposure to an alphavirus based on IgG reactivity to CHIKV VLP, with the highest risk observed in Kedougou (S1 Table). Modeling the presence of neutralizing antibodies to CHIKV against background factors showed that subjects aged over 40 years had higher odds of CHIKV infection after adjusting for age and gender (aOR, 2.094; 95% CI: 0.846-5.185), though this association was marginally significant (Table 3). Additionally, the prevalence of CHIKV neutralizing antibodies was higher in subjects aged over 40 years compared to the other age groups (Fig 1A). Furthermore, subjects from Thies were more likely to be infected with CHIKV (aOR, 3.147; 95% CI: 1.164-8.510) (Table 3), with a significantly higher prevalence of CHIKV neutralizing antibodies in this city compared to Sindia and Kedougou (Fig 1B). Residence of Kedougou was associated with significantly lower odds of contracting CHIKV (aOR, 0.606; 95% CI: 0.217-1.692) (Table 3).

For ONNV, univariate analysis, adjusted for age and gender, revealed that subjects aged over 40 years (aOR, 2.745; 95% CI: 1.212-6.216) had significantly increased odds of infection (Table 3), with a significantly higher prevalence of ONVV

neutralizing antibodies in this age group compared to the other age groups (Fig 1A).

Subjects aged 21 to 40 (aOR, 0.682; 95% CI: 0.304-1.531) years were associated with

lower odds of ONNV infection (Table 3). Being a resident of Kedougou (aOR, 3.888; 95%

CI: 1.319-11.466) was associated with increase odds of ONNV infection (Table 3), with

significantly higher prevalence of ONVV neutralizing antibodies compared to the other

cities (Fig 2B). Residence from Thies was associated with lower odds of infection (aOR,

0.764; 95% CI: 0.179-3.256) (Table 3).

Discussion

In this study, we observed an overall alphavirus prevalence of 38.5% with notable

geographical variations. Virus-specific analysis revealed prevalence rates of 7.4% for

CHIKV exposure and 9.8% for ONNV, both exhibiting significant geographical and age-

related variations. Cross-reactivity analysis showed that 82.9% of CHIKV cases exhibited

a neutralizing response to ONNV, while 71.7% of ONNV cases cross-neutralized CHIKV.

Older age emerged as a significant risk factor for ONNV exposure, and to a lesser extent

CHIKV. Additionally, ONNV exposure was significantly associated with residence in

Kedougou, while CHIKV exposure was strongly linked to residence in Thies. These

findings emphasize the continued transmission of alphaviruses in Senegal, specifically

CHIKV and ONNV, driven by geographic location as well as age-susceptibility.

The first documentation of a CHIKV human infection dates back to 1966 in

Rufisque, a city near Dakar, as part of arbovirus surveillance programs led by the Institut

Pasteur de Dakar. During this surveillance, CHIKV was detected in both mosquito vectors

and in human populations (29). Since then, numerous reports have documented CHIKV

circulation in the country, highlighting its endemicity and periodic re-emergence. A notable

example is the recent outbreak of CHIKV in Kedougou, which was attributed to the re-

emergence of an endemic strain (27).

To date, seroprevalence studies aimed at understanding CHIKV circulation in

Senegal have predominantly relied on detecting anti-CHIKV IgG antibodies using ELISA

(34, 35). However, this approach tends to overestimate CHIKV prevalence due to the

significant cross-reactivity between CHIKV and related alphaviruses, particularly ONNV.

This limitation highlights the need for more specific diagnostic methods, such as virus

neutralization assays or molecular techniques, to accurately discern CHIKV exposure and

better differentiate it from other co-circulating alphaviruses. Consequently, the use of a

microneutralization assay in this study allowed us to identify subjects with specific or

cross-reactive responses to either CHIKV or ONNV, providing a more accurate

assessment of their respective seroprevalence rates.

The prevalence rates for CHIKV and ONNV observed in our study differs from

those reported in similar studies in Senegal and other countries. For instance, a recent

study in Kedougou, involving inhabitants of 120 randomly selected villages, reported a

CHIKV prevalence of 54% (35), which is higher than both our overall observed rate and

the prevalence among the subjects from Kedougou in our study. An explanation for the

higher rate in this study is likely due to implementation of an anti-CHIKV IgG ELISA, which

measures cross-reactive alphavirus antibodies. In Nigeria, a systematic review

encompassing published literature spanning four decades reported a CHIKV prevalence

of 46.1% (36) based on neutralizing antibodies, a rate higher than that observed in the

present study. Additionally, our observed CHIKV prevalence rate is lower than the 56.5%

(37) reported among blood donors in Burkina Faso. Conversely, a study conducted in

Kenya reported CHIKV prevalence of 9.8% (38) among children from four communities

within the coastal and western regions, a rate comparable to our findings.

For ONNV, the prevalence rate observed in our study is lower than the 54.5% (37)

reported among blood donors in Burkina Faso, and the 28.4% (39) reported among HIV

patients in Madagascar. Importantly, both studies used anti-CHIKV IgG ELISAs to

measure antibody responses, which may have skewed the higher rates. Additionally,

modeling studies in Mali, using serological data estimated an ONNV prevalence of 30%

(33), also exceeding our observed rate. These discrepancies may be attributed to

differences in study population, sample size, methodological approaches, and ecological

or environment factors that influence virus transmission.

Our univariate logistic regression analysis identified older age as a risk factor for

both CHIKV and ONNV infection. We observed a higher prevalence of neutralizing

antibodies for both viruses in the older age group compared to their younger counterparts,

corroborating the notion that cumulative exposure over time contributes to higher

exposure rates. This demographic insight is crucial for developing targeted public health

strategies, especially for vaccine deployment and vector control initiatives. The

identification of older age as a risk factor for CHIKV infection is consistent with similar

findings from a study in Burkina Faso (37).

Furthermore, residents of Thies showed a three-fold increase in the likelihood of

CHIKV infection compared to other regions, as evidenced by the higher prevalence of

CHIKV neutralizing antibodies in Thies. Conversely, residents of Kedougou showed a

four-fold increase in the likelihood of ONNV infection, as evidenced by higher prevalence

of ONNV neutralizing antibodies compared to the other regions. These regional

differences may be attributed to distinct local vector ecologies or differences in human

activities that increase exposure to virus-specific mosquito vectors. These hypotheses

require further research.

We also observed that the prevalence of cross-neutralizing antibodies against

ONNV was higher among subjects with CHIKV neutralizing antibodies compared to those

with ONNV neutralizing antibodies exhibiting cross-neutralization against CHIKV. These

findings corroborate a directional bias in immune cross-reactivity, where CHIKV exposure

might confer broader immunity, potentially impacting subsequent ONNV infection

dynamics (33). This asymmetric cross-reactivity could also be due to structural similarities

in the viral envelope proteins of CHIKV and ONNV, with CHIKV eliciting a broader

neutralizing response (33). This phenomenon is crucial for diagnostic tests, which may

need differentiation between past infections of these two viruses based on neutralizing

antibody profiles. Moreover, understanding the mechanisms behind this differential cross-

reactivity could guide vaccine strategies where a vaccine against one virus might offer

partial protection against the other, hence optimizing the control measures for both

viruses in regions where they co-circulate.

One of the strengths of this study is our robust delineation of subjects previously

exposed to CHIKV or ONNV in Senegal, achieved through the use of neutralization

assays to minimize cross-reactivity. This methodological rigor makes our study the first

to report the co-circulation of these antigenically related viruses in the country, providing

valuable insights into their epidemiology and the public health risks they pose.

Despite its strengths, our study has several limitations. Of the 180 samples positive

for alphavirus IgG by ELISA, we were only able to perform neutralization assays on 117

due to sample availability. This limitation likely led to an underestimation of the true

prevalence of CHIKV and ONNV in our study populations. Additionally, while our use of

neutralization assays minimized cross-reactivity compared to the ELISA, a large

percentage of samples were considered equivocal, consistent with findings from other

studies. In contrast, other studies that rely solely on ELISA often classify these equivocal

results as positive, leading to potential overestimations of CHIKV prevalence (34, 35, 37).

Our approach provides a more conservative and potentially accurate estimate but

underscores the need for improved diagnostic tools to address the challenge of equivocal

results in alphavirus seroprevalence studies. Moreover, without concurrent clinical data,

we also cannot definitively link our serological findings to symptomatic disease cases,

underestimating the true burden of these infections. Additionally, the insights into antibody

cross-reactivity are essential for the interpretation of seroprevalence data in regions

endemic to both viruses, as they could lead to overestimations of immunity against one

virus due to past exposure to the other. This is particularly relevant in vaccine efficacy

trials and in the evaluation of natural immunity in the population.

Conclusions drawn from our research illustrate the persistent circulation of CHIKV

and ONNV in Senegal, necessitating sustained surveillance and public health

preparedness to mitigate the impact of these and other arboviruses. The findings also

emphasize the importance of ecological and demographic factors in shaping the

epidemiology of these diseases, highlighting the need for comprehensive arbovirus

control strategies that integrate vector management with community health initiatives.

Future studies should aim to incorporate entomological and clinical data to provide a more

holistic understanding of the transmission dynamics and to facilitate the development of

targeted interventions, including vaccines and therapeutic measures.

Acknowledgements

342 We would like to thank Rutgers Global Health Institute, Rutgers Robert Wood Johnson

343 Medical School, and the Child Health Institute of New Jersey.

Conflicts of Interest

346 BBH is a co-founder of Mir Biosciences, Inc., a biotechnology company that develops

347 diagnostics and vaccines for infectious diseases, cancer, and autoimmunity.

Author Contributions

Conceptualization: BBH

Data curation: PBT, MS, IMN, MT, AG, MA, BBH, DN

Formal analysis: PBT, MS, IMN, MT, AG, MA, BBH, DN

Funding acquisition: BBH, DN

Investigation: PBT, MS, IMN, MT, AG, MA, BBH, DN

Methodology: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY, YD, BD, KD,

MCS, ASB, BBH, DN

Project administration: BBH, DN

Resources: BBH, DN

Software: PBT, MS, BBH

Supervision: BBH, MS, DN

Validation: PBT, MS, IMN, MT, AG, MA, BBH, DN

Visualization: PBT, MS, IMN, MT, AG, MA, BBH, DN

Writing – original draft: PBT, BBH

Writing – review & editing: PBT, MS, IMN, MT, AG, MA, AMM, AKD, MAD, JFG, MSY,

YD, BD, KD, MCS, ASB, BBH, DN

References

1. Pezzi L, LaBeaud AD, Reusken CB, Drexler JF, Vasilakis N, Diallo M, et al.

GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 2:

Epidemiological distribution of o'nyong-nyong virus. Antiviral Res. 2019;172:104611.

2. Zaid A, Burt FJ, Liu X, Poo YS, Zandi K, Suhrbier A, et al. Arthritogenic

alphaviruses: epidemiological and clinical perspective on emerging arboviruses. Lancet

Infect Dis. 2021;21(5):e123-e33.

3. Renault P, Balleydier E, D'Ortenzio E, Baville M, Filleul L. Epidemiology of

Chikungunya infection on Reunion Island, Mayotte, and neighboring countries. Med Mal

Infect. 2012;42(3):93-101.

4. Wahid B, Ali A, Rafique S, Idrees M. Global expansion of chikungunya virus:

mapping the 64-year history. Int J Infect Dis. 2017;58:69-76.

5. Zeller H, Van Bortel W, Sudre B. Chikungunya: Its History in Africa and Asia and

Its Spread to New Regions in 2013-2014. J Infect Dis. 2016;214(suppl 5):S436-S40.

6.   Pezzi L, Diallo M, Rosa-Freitas MG, Vega-Rua A, Ng LFP, Boyer S, et al.

GloPID-R report on chikungunya, o'nyong-nyong and Mayaro virus, part 5:

Entomological aspects. Antiviral Res. 2020;174:104670.

7.   Sergon K, Njuguna C, Kalani R, Ofula V, Onyango C, Konongoi LS, et al.

Seroprevalence of Chikungunya virus (CHIKV) infection on Lamu Island, Kenya,

October 2004. Am J Trop Med Hyg. 2008;78(2):333-7.

8.   Fischer M, Staples JE, Arboviral Diseases Branch NCfE, Zoonotic Infectious

Diseases CDC. Notes from the field: chikungunya virus spreads in the Americas -

Caribbean and South America, 2013-2014. MMWR Morb Mortal Wkly Rep.

2014;63(22):500-1.

9.   Manzoor KN, Javed F, Ejaz M, Ali M, Mujaddadi N, Khan AA, et al. The global

emergence of Chikungunya infection: An integrated view. Rev Med Virol.

2022;32(3):e2287.

10.   Teixeira MG, Andrade AM, Costa Mda C, Castro JN, Oliveira FL, Goes CS, et al.

East/Central/South African genotype chikungunya virus, Brazil, 2014. Emerg Infect Dis.

2015;21(5):906-7.

11.   Corbet PS, Williams MC, Gillett JD. O'Nyong-Nyong fever: an epidemic virus

disease in East Africa. IV. Vector studies at epidemic sites. Trans R Soc Trop Med Hyg.

1961;55:463-80.

12.   Williams MC, Woodall JP, Corbet PS, Gillett JD. O'nyong-Nyong Fever: An

Epidemic Virus Disease in East Africa. 8. Virus Isolations from Anopheles Mosquitoes.

Trans R Soc Trop Med Hyg. 1965;59:300-6.

13.   Lanciotti RS, Ludwig ML, Rwaguma EB, Lutwama JJ, Kram TM, Karabatsos N,

et al. Emergence of epidemic O'nyong-nyong fever in Uganda after a 35-year absence:

genetic characterization of the virus. Virology. 1998;252(1):258-68.

14.   Rezza G, Chen R, Weaver SC. O'nyong-nyong fever: a neglected mosquito-

borne viral disease. Pathog Glob Health. 2017;111(6):271-5.

15.   Williams MC, Woodall JP, Gillett JD. O'nyong-Nyong Fever: An Epidemic Virus

Diesease in East Africa. Vii. Virus Isolations from Man and Serological Studies up to

July 1961. Trans R Soc Trop Med Hyg. 1965;59:186-97.

16.   Kiwanuka N, Sanders EJ, Rwaguma EB, Kawamata J, Ssengooba FP, Najjemba

R, et al. O'nyong-nyong fever in south-central Uganda, 1996-1997: clinical features and

validation of a clinical case definition for surveillance purposes. Clin Infect Dis.

1999;29(5):1243-50.

17.   Tappe D, Kapaun A, Emmerich P, Campos Rde M, Cadar D, Gunther S, et al.

O'nyong-nyong virus infection imported to Europe from Kenya by a traveler. Emerg

Infect Dis. 2014;20(10):1766-7.

18.   Johnson BK. O'nyong-nyong virus disease. Arboviruses: CRC Press; 2019. p.

217-24.

19.   Kucharz EJ, Cebula-Byrska I. Chikungunya fever. Eur J Intern Med.

2012;23(4):325-9.

20.   Schilte C, Staikovsky F, Couderc T, Madec Y, Carpentier F, Kassab S, et al.

Chikungunya virus-associated long-term arthralgia: a 36-month prospective longitudinal

study. PLoS neglected tropical diseases. 2013;7(3):e2137.

21. Al-Emran HM, Eibach D, Krumkamp R, Ali M, Baker S, Biggs HM, et al. A

multicountry molecular analysis of Salmonella enterica serovar Typhi with reduced

susceptibility to ciprofloxacin in sub-Saharan Africa. Clinical Infectious Diseases.

2016;62(suppl_1):S42-S6.

22. Badiane AS, Ngom B, Ndiaye T, Cunningham D, Campbell J, Gaye A, et al.

Evidence of Plasmodium vivax circulation in western and eastern regions of Senegal:

implications for malaria control. Malaria Journal. 2024;23(1):149.

23. Diallo A, Sié A, Sirima S, Sylla K, Ndiaye M, Bountogo M, et al. An

epidemiological study to assess Plasmodium falciparum parasite prevalence and

malaria control measures in Burkina Faso and Senegal. Malaria journal. 2017;16:1-12.

24. Diallo M, Diongue K, Diagne G, Seck M, Ndiaye M, Dièye B, et al. Plasmodium

ovale wallikeri and Plasmodium ovale curtisi Malaria in Senegal in 2016. Bulletin de la

Société de pathologie exotique. 2017;110:286-90.

25. Dromigny J-A, Perrier-Gros-Claude J-D. Antimicrobial resistance of Salmonella

enterica serotype Typhi in Dakar, Senegal. Clinical infectious diseases. 2003;37(3):465-

6.

26. Harrois D, Breurec S, Seck A, Delauné A, Le Hello S, de La Gandara MP, et al.

Prevalence and characterization of extended-spectrum β-lactamase-producing clinical

Salmonella enterica isolates in Dakar, Senegal, from 1999 to 2009. Clinical

Microbiology and Infection. 2014;20(2):O109-O16.

27. Dieng I, Sadio BD, Gaye A, Sagne SN, Ndione MHD, Kane M, et al. Genomic

characterization of a reemerging Chikungunya outbreak in Kedougou, Southeastern

Senegal, 2023. Emerg Microbes Infect. 2024;13(1):2373308.

28.   Pistone T, Ezzedine K, Boisvert M, Receveur MC, Schuffenecker I, Zeller H, et

al. Cluster of chikungunya virus infection in travelers returning from Senegal, 2006. J

Travel Med. 2009;16(4):286-8.

29.   Roche S, Robin Y. [Human infections by Chikungunya virus in Rufisque

(Senegal), October-November, 1966]. Bull Soc Med Afr Noire Lang Fr. 1967;12(3):490-

6.

30.   Saluzzo J, Cornet M, Digoutte J. Outbreak of a Chikungunya virus epidemic in

western Senegal in 1982. Dakar medical. 1983;28(3):497-500.

31.   Sow A, Faye O, Diallo M, Diallo D, Chen R, Faye O, et al. Chikungunya Outbreak

in Kedougou, Southeastern Senegal in 2009-2010. Open Forum Infect Dis.

2018;5(1):ofx259.

32.   LaBeaud AD, Banda T, Brichard J, Muchiri EM, Mungai PL, Mutuku FM, et al.

High rates of o'nyong nyong and Chikungunya virus transmission in coastal Kenya.

PLoS Negl Trop Dis. 2015;9(2):e0003436.

33.   Hoze N, Diarra I, Sangare AK, Pastorino B, Pezzi L, Kouriba B, et al. Model-

based assessment of Chikungunya and O'nyong-nyong virus circulation in Mali in a

serological cross-reactivity context. Nat Commun. 2021;12(1):6735.

34.   de Souza WM, Gaye A, Ndiaye EH, Morgan AL, Sylla EHD, Sy FA, et al.

Serosurvey of Chikungunya Virus in Old World Fruit Bats, Senegal, 2020-2022. Emerg

Infect Dis. 2024;30(7):1490-2.

35.   Sow A, Nikolay B, Faye O, Cauchemez S, Cano J, Diallo M, et al. Changes in the

Transmission Dynamic of Chikungunya Virus in Southeastern Senegal. Viruses.

2020;12(2).

36.   Abdullahi IN, Akande AO, Muhammed Y, Rogo LD, Oderinde BS. Prevalence

Pattern of Chikungunya Virus Infection in Nigeria: A Four Decade Systematic Review

and Meta-analysis. Pathog Glob Health. 2020;114(3):111-6.

37.   Tinto B, Bicaba B, Kagoné TS, Kayiwa J, Rabe I, Merle CSC, et al. Co-circulation

of two Alphaviruses in Burkina Faso: Chikungunya and O'nyong nyong viruses. PLoS

Negl Trop Dis. 2024;18(6):e0011712.

38.   Khan A, Bisanzio D, Mutuku F, Ndenga B, Grossi-Soyster EN, Jembe Z, et al.

Spatiotemporal overlapping of dengue, chikungunya, and malaria infections in children

in Kenya. BMC Infect Dis. 2023;23(1):183.

39.   Rakotomalala FA, Bouillin J, Randriarimanana SD, Thaurignac G, Maharavo L,

Raberahona M, et al. High Seroprevalence of IgG Antibodies to Multiple Arboviruses in

People Living with HIV (PLWHIV) in Madagascar. Viruses. 2023;15(11).

494 **Tables**

496 **Table 1. Baseline characteristics and chikungunya virus (CHIKV) and o'nyong-**

497 **nyong virus (ONNV) serology**

	Sindia (n=94)	Thies (n=94)	Kedougou (n=282)	Total (n=470)
Demographics				
Year(s) samples collected	2018	2018	2022-2023	
Age group, n (%)				
≤ 20 years	40 (42.6)	48 (41.1)	136 (48.2)	224 (47.7)
21-40 years	42 (44.7)	23 (24.4)	123 (43.6)	188 (40.0)
> 40 years	11 (11.7)	23 (24.4)	21 (7.5)	55 (11.7)
Unreported	1 (1.0)	_	2 (0.7)	3 (0.6)
Female gender, n (%)	39 (41.5)	51 (54.3)	121 (42.9)	211 (44.9)
History of malaria infection, n (%)	0 (0)	0 (0)	282 (100)	282 (60)
Serology				
CHIKV VLP IgG+, n (%)	14 (14.9)	30 (31.9)	137 (48.6)	181 (38.5)
NT50, n (%)				
CHIKV	6 (6.4)	18 (19.1)	11 (3.9)	35 (7.4)
ONNV	4 (4.3)	4 (4.3)	38 (13.5)	46 (9.8)
Equivocal	4 (4.3)	5 (5.3)	15 (5.3)	24 (5.1)
Negative	0 (0.0)	0 (0.0)	12 (4.3)	12 (2.6)

Table 2. Baseline characteristics of NT50-confirmed chikungunya virus (CHIKV) and o'nyong-nyong virus (ONNV) subjects

	Total n= 470	CHIKV NT50-confirmed subjects n=35	ONNV NT50-confirmed subjects n=46
Age group, n (%)			
≤ 20 years	224 (47.7)	17 (7.6)	19 (8.5)
21-40 years	188 (40.0)	10 (5.3)	15 (8.0)
> 40 years	55 (11.7)	8 (14.8)	11 (20.0)
Unreported	3 (0.6)	0 (0.0)	1 (33.3)
Gender, n (%)			
Male	256 (54.5)	18 (7.0)	26 (10.2)
Female	211 (44.9)	17 (8.0)	20 (9.5)
Unreported	3 (0.6)	0 (0.0)	0 (0.0)
City, n (%)			
Sindia	94 (20.0)	6 (6.4)	4 (4.3)
Thies	94 (20.0)	18 (19.1)	4 (4.3)
Kedougou	282 (60.0)	11 (3.9)	38 (13.5)
History of malaria infection, n (%)	282 (60)	11 (3.9)	38 (13.5)

Table 3. Risk factors for chikungunya virus (CHIKV) and o'nyong-nyong virus (ONNV) infections in Senegal

Predictor	Univariate binary logistic regression			
	OR (95% CI)	p value	aOR (95% CI)	p value
CHIKV NT50-confirmed subjects				
Age group				
≤ 20 years	Reference	0.077	Reference	0.082
21-40 years	0.687 (0.307-1.539)		0.682 (0.304-1.531)	
> 40 years	2.128 (0.866-5.228)		2.094 (0.846-5.185)	
Gender				
Male	Reference		Reference	
Female	1.153 (0.579-2.297)	0.686	1.100 (0.546-2.213)	0.79
City				
Sindia	Reference	<0.001	Reference	<0.001
Thies	3.474 (1.312-9.196)		3.147 (1.164-8.510)	
Kedougou	0.595 (0.214-1.657)		0.606 (0.217-1.692)	
ONNV NT50-confirmed subjects				
Age group				
≤ 20 years	Reference	0.027	Reference	0.026
21-40 years	0.936 (0.462-1.896)		0.948 (0.467-1.924)	
> 40 years	2.697 (1.199-6.068)		2.745 (1.212-6.216)	
Gender				
Male	Reference		Reference	
Female	0.926 (0.501-1.711)	0.807	0.897 (0.478-1.683)	0.736
City				
Sindia	Reference	0.008	Reference	0.002
Thies	1.000 (0.243-4.122)		0.764 (0.179-3.256)	
Kedougou	3.504 (1.216-10.096)		3.888 (1.319-11.466)	

OR- Crude odd ratio; aOR- adjusted odd ratio for gender and age

Figures

Fig 1. Comparison of the prevalence of neutralizing antibodies to CHIKV and ONNV by age group, city, and gender. Differences between (A) age, (B) city, and (C) gender were assessed using the Chi-square test or Fisher's exact test, as appropriate. P-values less than 0.05 were considered to be statistically significant, while values less than 0.1 were considered to be marginally significant.

Fig. 2. Antibody neutralization against chikungunya (CHIKV) and o'nyong-nyong (ONNV) viruses in Senegal. (A) Map depicts locations in Senegal (Sindia, Thies, and Kedougou) where samples were collected from non-febrile subjects. For each location, bar charts represent the neutralizing antibody prevalence against CHIKV (C) or ONNV (C), or equivocal (E) and negative (N) results. Prevalence values are listed above each bar. (B) CHIKV virus-like particle IgG-positive samples (n=117) were tested for neutralizing antibodies against CHIKV and ONNV. Colors depict the 50% neutralizing antibody titers (NT50), each row represents one individual, and each column is the titer to CHIKV or ONNV. (C) The percentage of NT50-confirmed CHIKV or ONNV subjects with cross-neutralizing antibodies to the heterologous virus.